Open access

Patient-derived ascites reveals functional advantages of γδCAR T-cells within the ovarian cancer-like tumor microenvironment

Paula Hahn Katerina Ntarntani Isabella Micallef Nilsson Emilija Gailiesaite E. Foord Michael Uhlin Isabelle Magalhaes Thomas Poiret

Sep 2026 · bioRxiv · 0 citations

Biology

TL;DR

These findings reveal specific functional advantages of γδCAR T-cells over convCAR T-cells in the immunosuppressive OVCA TME-like condition while facing different cellular fitness constraints, providing insights into the use and limitations of γδCAR T-cells.

DOI Semantic Scholar

Read PDF

Similar papers

Sep 2026

Abstract B100: Targeting orthotopic and metastatic pancreatic cancer with allogeneic stem cell–engineered mesothelin-redirected CAR-engineered invariant natural killer T cells

Pancreatic cancer (PC) remains one of the leading causes of cancer-related mortality worldwide, with most patients diagnosed at advanced stages and more than half presenting with metastatic disease at diagnosis. Although chimeric antigen receptor (CAR)-T cell therapy has shown promise for the treatment of PC, its cli...

Yan-Ruide Li, Xin-Yuan Shen, En-Bo Zhu et al. · Cancer Research · 0 citations

Open access Sep 2026

CD28-ICOS costimulation enhances the therapeutic efficacy of L1CAM-targeted CAR-T cells against ovarian and gastric cancers

The combination of rational CAR design (CD28-ICOS signaling) and optimized delivery strategy provides a strong rationale for the clinical development of L1CAM-targeted CAR-T therapy, particularly in patients with L1CAM-positive solid tumors.

X. Che, Un-Jung Yun, Junsub Lee et al. · Journal for ImmunoTherapy of... · 0 citations

Aug 2026

Humanized CD70-targeted CAR-T cells with reduced fratricide demonstrate potent antitumor activity against AML and RCC.

A humanized CD70-targeted CAR-T cell therapy is developed, A174-hu1-CAR-T, with reduced fratricide and potent antitumor activity, providing a preclinical foundation to support further translational development.

Meng-Jia Zhang, Zhi-Hao Wang, Cheng Gao et al. · International Immunopharmaco... · 1 citation

Open access Sep 2026

29 Engineering CD16-Enhanced Stem Cell–Derived Universal NKT Cells to Potentiate Anti-CD70 Therapy in Renal Cell Carcinoma

CD16HSC-NKT cells are established as a versatile and scalable cellular platform that synergizes with cusatuzumab to enhance therapeutic efficacy against RCC, and represent a promising approach to overcoming current limitations of monoclonal antibody therapy and advancing next-generation immunotherapies for solid tumors...

Yan-Ruide Li, Yi-Chen Zhu, Yu-Ning Chen et al. · The Oncologist · 0 citations

Open access Oct 2026

Metabolic Rewiring of GPC3-Targeted CAR T Cells Expressing IL-15 and HER2-Targeted CAR T Cells via the ADA1–CD26 Axis Promotes Tumor Infiltration and Limits Systemic Toxicities

Background: Chimeric antigen receptor (CAR) T-cell therapy for solid tumors is limited by inadequate T-cell persistence and tumor infiltration, as well as treatment-associated cytokine release syndrome (CRS). To address these challenges, we developed a metabolically rewired CAR T-cell (MRCAR) platform by co-expressing...

Yue Hu, Kevin Song, Ruo-Ning Wang et al. · Biomedicines · 0 citations

Open access Sep 2026

Preclinical evaluation of SLC35D3-targeted CAR-T cells for tumor-selective immunotherapy

Chimeric antigen receptor (CAR)-T therapy has transformed management of hematological malignancies, yet efficacy in solid tumors is limited by scarcity of tumor-restricted antigens. Here we characterize SLC35D3, a nucleotide-sugar transporter that we previously identified through integrated transcriptomic and protein-l...

Shunsuke Someya, Ming-Ma Ming, Wataru Tomisato et al. · Biochemistry and Biophysics... · 0 citations